Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22230040 | 0.81 | PIK3CD (0.43) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL26098721 | 0.77 | CHRNB2 (0.38) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL26133178 | 0.77 | CHRNB2 (0.38) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL30111779 | 0.73 | PDE10A (0.39) | CHRNB2CHRNA4MEN1KMT2ANPC1 | |
| SCHEMBL28906165 | 0.73 | PDE10A (0.39) | CHRNB2CHRNA4MEN1KMT2ANPC1 | |
| SCHEMBL29050472 | 0.72 | MEN1 (0.47) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL24185712 | 0.70 | SMN1; SMN2 (0.54) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL16200199 | 0.69 | MEN1 (0.43) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL16200254 | 0.69 | MEN1 (0.47) | CHRNB2CHRNA4PIK3CDMEN1KMT2A | |
| SCHEMBL8108697 | 0.68 | SLC34A1 (0.38) | CHRNB2CHRNA4PIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| CN-119112897-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119119022-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119119023-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| CN-119060040-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-3911648-B1 | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| CN-113574055-B | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-113574055-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113412258-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-09-17 | — | — | CN | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-07-23 | — | — | US | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-07-23 | — | — | US | disclosed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | CHRNB2 4635/4885CHRNA4 4775/4885PIK3CD 1529/4885 |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | CHRNB2 3457/4885CHRNA4 3775/4885PIK3CD 2750/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | CHRNB2 2224/4885CHRNA4 2614/4885PIK3CD 3917/4885 |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | CHRNB2 3799/4885CHRNA4 4400/4885PIK3CD 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.